Curated Journal Articles on Mesothelioma

IMP3 as a prognostic biomarker in patients with malignant peritoneal mesothelioma.

Human Pathology 2018 July 18 [Link]

Hui S, Guo-Qi Z, Xiao-Zhong G, Chun-Rong L, Yu-Fei L, Dong-Liang Y


Malignant peritoneal mesothelioma (MPeM) is an incurable cancer with poor prognosis and several biomarkers have been suggested for screening of MPeM. The aim of our study was to evaluate the prognostic significanceas of IMP3 and Fli-1 in MPeM. Diagnostic biopsies of 44 MPeM patients were centrally collected and were immunohistochemically analyzed for expression of IMP3, Fli-1, and Ki-67. Labelling was assessed by two pathologists. Complete clinical information and follow up were obtained from patients’ records. Carcinomas expressed Fli-1 in 42(95.5%) of 44 specimens, and IMP3 in 23 (52.3%) of 44 specimens. Spearman’s rho analysis revealed Fli-1 expression was related to both histological type and Ki-67LI (r=-0.500, P<.05; r=0.358, P<.05), and IMP3 expression was related to Ki-67LI (r=0.401, P<.05). A Kaplan-Meier analysis and univariate Cox regression analysis showed that tumor-directed treatment, a lower PCI, Stage I, lower Ki-67LI and lower level IMP3 expression had a statistically significantly positive effect on overall survival; Fli-1 did not affect overall survival in the univariate analysis (hazard ratio [HR]=1.026, P=.904). A Kaplan-Meier analysis showed the correlation between IMP3-Fli-1 and overall survival, while univariate and multivariate Cox regression analysis did not confirm the correlation. Cox regression analysis revealed that IMP3 expression (HR=2.311[95%CI 1.190-4.486]; P=.013) and no tumor-directed treatment (HR=0.189[95%CI 0.086-0.416]; P=.000) retained independent prognostic significance, both with negative effect on OS. IMP3, along with tumor-directed treatment protocols, is a powerful prognosticator in patients with MPeM.

Both comments and trackbacks are currently closed.